Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Elastic NV (ESTC) vs TransMedics Group Inc (TMDX) Price & Performance

Elastic NVTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Elastic NV vs TransMedics Group Inc — how do they compare? Elastic NV trades at $77.12 (market cap $7.94B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Elastic NV is far larger — about 2.6× TransMedics Group Inc's market cap, and Elastic NV is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.

ESTCTMDX
Market Cap
$7.94B$3.10B
Sector
TechnologyTechnology
52-Week High
$94.47$150.42
52-Week Low
$43.30$61.99
Enterprise Value
$7.16B$3.49B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Elastic NV

Elastic N.V. (ESTC) trades at $77.16, up 1.1% with a bullish technical outlook. The stock shows strong profitability with a 76.07% gross margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights include a collaboration with OpenAI and recognition as a leader in Gartner's Magic Quadrant for Observability Platforms. Institutional activity is mixed, with Amundi increasing its stake while BNY Mellon reduced its position.

The outlook is positive, supported by earnings momentum and strategic partnerships, but risks include high valuation multiples and a recent legal investigation. Analyst consensus is bullish with a $74.21 price target, though the current price exceeds this, indicating potential near-term consolidation. Revenue growth and AI integration present key opportunities for long-term investors.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.

The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.

Returns comparison

Trailing returns across standard periods

About Elastic NV

Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.

Read more on ESTC

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX